Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

NCT05836987 · View on ClinicalTrials.gov ↗

Study Summary

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

Conditions Studied

Interventions

  • DEVICE AFSW Guided DOAC
  • DRUG Continuous DOAC therapy

Study Locations (20)

Florida

  • BayCare Health Systems — Clearwater
  • University of Florida — Gainesville
  • Mayo Clinic — Jacksonville
  • University of Miami - Leonard S. Miller SOM — Miami
  • Sarasota Memorial Health Care System — Sarasota
  • Cleveland Clinic Florida — Stuart
  • Baycare Health Systems Clearwater — Winter Haven

California

  • University of Southern California - Keck School of Medicine — Los Angeles
  • University of California Los Angeles (UCLA Health) — Los Angeles
  • UC Davis Health — Sacramento
  • Scripps Health — San Diego
  • Stanford University — Stanford

Colorado

  • University of Colorado — Aurora
  • South Denver Cardiology Associates, P.C. — Littleton

District of Columbia

  • St. Elizabeth's Medical Center — Washington D.C.
  • Medical Faculty Associates George Washington University — Washington D.C.

Georgia

  • Emory University — Atlanta
  • Georgia Arrhythmia Consultants and Research Institute — Warner Robins

Arizona

  • Banner University — Phoenix

Illinois

  • University of Illinois Chicago — Chicago

Trial Details

FieldValue
Enrollment Target 5,350 participants
Start Date 2023-07-13
Est. Completion 2029-07-31
Phase Phase 3

Sponsor

Johns Hopkins University

1,517 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05836987

The ClinicalTrials.gov registry entry for NCT05836987 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,517 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions — of which AFSW Guided DOAC is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05836987 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05836987 about?

NCT05836987 is a clinical study titled "The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation". REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in partic...

What is the current status of trial NCT05836987?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,350 participants. The study started on 2023-07-13. Estimated completion is 2029-07-31.

What conditions does trial NCT05836987 study?

This clinical trial studies the following conditions: Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05836987?

The interventions under investigation include: AFSW Guided DOAC (DEVICE), Continuous DOAC therapy (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05836987?

This trial is sponsored by Johns Hopkins University, which has 1,517 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05836987 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial